NCT00194714View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

March 31, 2021

Study Completion Date

May 22, 2023

Conditions
HER2/Neu PositiveHLA-A2 Positive Cells PresentStage IV Breast CancerStage IV Ovarian Cancer
Interventions
BIOLOGICAL

HER-2/neu Peptide Vaccine

Given ID

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER

collaborator

National Cancer Institute (NCI)

NIH

NCT00194714 - Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | Biotech Hunter | Biotech Hunter